Myriad Genetics, Inc. (MYGN) Tops Q1 EPS by 4c; Boosts FY13 Outlook
Tweet
Share
E-mailGet Alerts MYGN Hot Sheet
Price: $3.04 +0.33%
Financial Fact:
Cost of molecular diagnostic testing: 34.3M
Today's EPS Names:
MSGM, SMID, VISL, More
Financial Fact:
Cost of molecular diagnostic testing: 34.3M
Today's EPS Names:
MSGM, SMID, VISL, More
Join SI Premium – FREE
Myriad Genetics, Inc. (NASDAQ: MYGN) reported Q1 EPS of $0.36, $0.04 better than the analyst estimate of $0.32. Revenue for the quarter came in at $133.44 million versus the consensus estimate of $129.43 million.
Myriad Genetics, Inc. sees FY2013 EPS of $1.50-1.55, versus prior guidance of $1.44-1.48 and the consensus of $1.47. Myriad Genetics, Inc. sees FY2013 revenue of $570-585 million, versus prior guidance of $550-565 million and the consensus of $563.5 million.
For earnings history and earnings-related data on Myriad Genetics, Inc. (MYGN) click here.
Myriad Genetics, Inc. sees FY2013 EPS of $1.50-1.55, versus prior guidance of $1.44-1.48 and the consensus of $1.47. Myriad Genetics, Inc. sees FY2013 revenue of $570-585 million, versus prior guidance of $550-565 million and the consensus of $563.5 million.
For earnings history and earnings-related data on Myriad Genetics, Inc. (MYGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- InspireMD (NSPR) Tops Q2 EPS by 1c
- The LGL Group (LGL) Misses Q2 EPS by 8c
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
